Aquestive Therapeutics SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 19, 2026, 4:04 p.m. ETView on SEC.gov
Amendments to articles or bylaws; fiscal year change · Financial statements and exhibits
AI summary, unreviewedAquestive Therapeutics Amends Bylaws to Remove Concert-Action Nomination Disclosure Requirements; No Financial Impact Disclosed
8-KOct. 15, 2026, 7:21 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
AI summary, unreviewedAquestive Therapeutics Gets FDA Acceptance of Anaphylm NDA Resubmission, PDUFA Date Set for March 16, 2027
8-KOct. 14, 2026, 7:21 a.m. ETView on SEC.gov
Entry into a material definitive agreement · Financial statements and exhibits
8-KSept. 29, 2026, 7:22 a.m. ETView on SEC.gov
Departure/appointment of directors or officers · Financial statements and exhibits
8-KSept. 25, 2026, 7:59 a.m. ETView on SEC.gov
Regulation FD disclosure · Financial statements and exhibits
8-KSept. 17, 2026, 7:02 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
8-KAug. 11, 2026, 4:06 p.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Financial statements and exhibits
8-KAug. 10, 2026, 7:05 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits